News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
271,340 Results
Type
Article (13998)
Company Profile (112)
Press Release (257230)
Section
Business (90125)
Career Advice (465)
Deals (15711)
Drug Delivery (64)
Drug Development (37950)
Employer Resources (49)
FDA (6842)
Job Trends (6352)
News (154563)
Policy (14367)
Tag
Academia (460)
Alliances (23724)
Alzheimer's disease (356)
Approvals (6830)
Artificial intelligence (63)
Bankruptcy (147)
Best Places to Work (4473)
Biotechnology (44)
Breast cancer (43)
Cancer (337)
Career advice (409)
Cell therapy (45)
Clinical research (31447)
Collaboration (165)
Compensation (68)
COVID-19 (762)
C-suite (52)
Data (371)
Diabetes (57)
Diagnostics (1341)
Drug pricing (57)
Earnings (32500)
Employer resources (43)
Events (38367)
Executive appointments (171)
FDA (7032)
Funding (110)
Gene therapy (61)
GLP-1 (297)
Government (1320)
Healthcare (3952)
Infectious disease (781)
Inflammatory bowel disease (46)
Interviews (58)
IPO (5984)
Job creations (2070)
Job search strategy (376)
Layoffs (171)
Legal (3453)
Lung cancer (51)
Manufacturing (102)
Medical device (1937)
Medtech (1939)
Mergers & acquisitions (9761)
Metabolic disorders (172)
Neuroscience (457)
NextGen Class of 2024 (1682)
Non-profit (610)
Northern California (491)
Obesity (100)
Opinion (110)
Patents (55)
People (28899)
Pharmaceutical (66)
Phase I (8432)
Phase II (13366)
Phase III (11730)
Pipeline (192)
Policy (45)
Postmarket research (1413)
Preclinical (3408)
Radiopharmaceuticals (121)
Rare diseases (93)
Real estate (2679)
Regulatory (10108)
Research institute (604)
Resumes & cover letters (56)
Southern California (450)
Startups (1671)
United States (4524)
Vaccines (124)
Weight loss (78)
Date
Today (37)
Last 7 days (282)
Last 30 days (1329)
Last 365 days (13409)
2024 (12242)
2023 (15022)
2022 (20628)
2021 (21184)
2020 (19938)
2019 (15504)
2018 (12270)
2017 (14445)
2016 (13615)
2015 (16045)
2014 (12866)
2013 (10956)
2012 (11711)
2011 (12272)
2010 (11152)
Location
Africa (317)
Arizona (44)
Asia (20524)
Australia (2615)
California (1100)
Canada (610)
China (112)
Colorado (47)
Connecticut (43)
Europe (39800)
Florida (159)
Illinois (115)
Indiana (86)
Japan (43)
Kansas (51)
Maryland (170)
Massachusetts (935)
Minnesota (64)
New Jersey (426)
New York (283)
North Carolina (286)
Northern California (491)
Pennsylvania (302)
South America (505)
Southern California (450)
Texas (148)
Virginia (41)
Washington State (72)
271,340 Results for "fusion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Acquisition of Fusion Pharmaceuticals Completed
Fusion Pharmaceuticals Inc. announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement.
June 4, 2024
·
6 min read
Deals
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca
Fusion Pharmaceuticals Inc. announced that at a special meeting of its shareholders, held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion.
May 29, 2024
·
4 min read
Business
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Fusion Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024, and provided an update on clinical and corporate developments.
May 7, 2024
·
15 min read
Genetown
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
Fusion Pharmaceuticals Inc. today announced that the Company will participate in two upcoming investor conferences.
February 26, 2024
·
2 min read
SAIL Fusion Announces the U.S. Commercial Launch of its BowTie™ Sacroiliac Fusion System
SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced the U.S. commercial launch of its novel BowTie Sacroiliac Fusion System.
June 12, 2024
·
3 min read
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the “Circular”) and related materials for the special meeting (the “Meeting”) of Fusion’s shareholders (the “Shareholders”) to approve the previously announced arrangement with AstraZeneca plc (“AstraZeneca”) under the Canada Business Corporations Act (the “Arrangement”).
April 25, 2024
·
9 min read
Biotech Beach
SAIL Fusion Announces FDA Clearance of its BowTie™ Sacroiliac Fusion System
SAIL Fusion, a medical device company focused on advancing the surgical treatment of sacroiliac joint dysfunction through solutions built upon proven AO principles, today announced that it has received FDA clearance for its novel BowTie Sacroiliac Fusion System.
April 23, 2024
·
3 min read
Deals
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radioconjugates as precision medicines, announced the Company has entered into a definitive agreement to be acquired by AstraZeneca.
March 19, 2024
·
12 min read
Business
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on clinical and corporate developments.
March 20, 2024
·
15 min read
Drug Development
Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC).
May 9, 2024
·
6 min read
1 of 27,134
Next